Dianthus Therapeutics (DNTH) Accounts Payables (2017 - 2025)

Dianthus Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $9.7 million for Q4 2025.

• In Q4 2025, Accounts Payables rose 112.38% year-over-year to $9.7 million; the TTM figure through Dec 2025 stood at $9.7 million (up 112.38% YoY), while the FY2025 annual figure was $9.7 million, up 112.38% from the prior year.
• Accounts Payables for Q4 2025 stood at $9.7 million, up from $6.7 million in the prior quarter.
• The five-year high for Accounts Payables was $9.7 million in Q4 2025, with the low at $813000.0 in Q2 2023.
• The 5-year median for Accounts Payables is $2.8 million (2021), against an average of $3.7 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables plunged 75.66% in 2023, then jumped 453.1% in 2024.
• Dianthus Therapeutics' Accounts Payables stood at $3.0 million in 2021, then slumped by 61.61% to $1.2 million in 2022, then surged by 123.65% to $2.6 million in 2023, then soared by 75.44% to $4.6 million in 2024, then jumped by 112.38% to $9.7 million in 2025.
• Business Quant data shows DNTH's Accounts Payables at $9.7 million in Q4 2025, $6.7 million in Q3 2025, and $5.4 million in Q2 2025.